Literature DB >> 21327564

Is subcutaneous bortezomib ready for prime time?

Sagar Lonial1.   

Abstract

Entities:  

Year:  2011        PMID： 21327564     DOI： 10.1007/s11899-011-0078-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


× No keyword cloud information.
  7 in total

1.  Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Authors:  Paul G Richardson; Hannah Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; Seema Singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

2.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

3.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Authors:  María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel
Journal:  Lancet Oncol       Date:  2010-08-23       Impact factor: 41.316

4.  A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.

Authors:  Sagar Lonial; Jonathan Kaufman; Mourad Tighiouart; Ajay Nooka; Amelia A Langston; Leonard T Heffner; Claire Torre; Stephanie McMillan; Heather Renfroe; R Donald Harvey; Mary J Lechowicz; H Jean Khoury; Christopher R Flowers; Edmund K Waller
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

5.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Authors:  Sara Bringhen; Alessandra Larocca; Davide Rossi; Maide Cavalli; Mariella Genuardi; Roberto Ria; Silvia Gentili; Francesca Patriarca; Chiara Nozzoli; Anna Levi; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Vincenzo Rizzo; Clotilde Cangialosi; Pellegrino Musto; Luca De Rosa; Anna Marina Liberati; Mariella Grasso; Antonietta P Falcone; Andrea Evangelista; Michele Cavo; Gianluca Gaidano; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

6.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Authors:  Jean-Luc Harousseau; Michel Attal; Hervé Avet-Loiseau; Gerald Marit; Denis Caillot; Mohamad Mohty; Pascal Lenain; Cyrille Hulin; Thierry Facon; Philippe Casassus; Mauricette Michallet; Hervé Maisonneuve; Lotfi Benboubker; Frédéric Maloisel; Marie-Odile Petillon; Iain Webb; Claire Mathiot; Philippe Moreau
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

7.  Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

Authors:  Philippe Moreau; Valerie Coiteux; Cyrille Hulin; Xavier Leleu; Helgi van de Velde; Milin Acharya; Jean-Luc Harousseau
Journal:  Haematologica       Date:  2008-09-02       Impact factor: 9.941
  7 in total
  1 in total

1.  High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.

Authors:  Tomohiko Kamimura; Toshihiro Miyamoto; Noriko Yokota; Takatoshi Aoki; Yoshikiyo Ito; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-11-19       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.